The committee for advanced therapies' of the European Medicines Agency reflection paper on management of clinical risks deriving from insertional mutagenesis. (2013)
Attributed to:
MICA: MRC Centre for Neuromuscular Diseases
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1089/humc.2013.119
PubMed Identifier: 23862696
Publication URI: http://europepmc.org/abstract/MED/23862696
Type: Journal Article/Review
Volume: 24
Parent Publication: Human gene therapy. Clinical development
Issue: 2
ISSN: 2324-8637